Faslodex 250mg / 5ml Injection
PDF Leaflet Revision Date: 7 June 2019
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women.
Dosage (summary)
500 mg intramuscularly as two 5 ml injections, one in each buttock, at 1-month intervals with an additional 500 mg dose 2 weeks after the initial dose.
Special Populations
- Hepatic impairment
- Renal insufficiency
Pregnancy & Breastfeeding
Avoid use in pregnancy and breastfeeding due to potential risks.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to ingredients
- Severe hepatic impairment
- Pregnancy
- Breastfeeding
Common side effects
- Injection site reactions
- Asthenia
- Nausea
- Hypersensitivity reactions
- Joint pain
- Hot flushes
Counselling Points
- Administer slowly (1-2 mins/injection)
- Monitor for hypersensitivity reactions
- Avoid driving if experiencing asthenia
Serious warnings
- Caution in hepatic impairment
- Caution in patients with creatinine clearance <30 ml/min
- Injection site related events
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
